Immunogenicity and safety of boosting with a recombinant two-component SARS-CoV-2 vaccine: two randomized, parallel-controlled, phase 2 studies

Recombinant protein vaccines are vital for broad protection against SARS-CoV-2 variants. This study assessed ReCOV as a booster in two Phase 2 trials. Study-1 involved subjects were randomized (1:1:1) to receive 20 μg ReCOV, 40 μg ReCOV, or an inactivated vaccine (COVILO®) in the United Arab Emirate...

Ausführliche Beschreibung

Bibliographische Detailangaben

Hauptverfasser:	Balgos, Abundio, Hannawi, Suad, Chen, Wen-Li, Abuquta, Alaa, Safeldin, Linda, Hassan, Aala, Alamadi, Ahmad, Tirador, Louie, Jaen, Anjuli May, Villalobos, Ralph Elvi, Mo, Chen, Yue, Zi-Jing, Ma, Ying, Wang, Qing-Shuang, Wen, Ren-Du, Yao, Zheng, Yu, Jia-Ping, Yao, Wen-Rong, Zhang, Jian-Hui, Hong, Kun-Xue, Liu, Yong, Li, Jing-Xin
Format:	Dataset
Sprache:	eng
Schlagworte:	Biotechnology Cell Biology FOS: Biological sciences FOS: Clinical medicine FOS: Health sciences Immunology Infectious Diseases Mental Health Microbiology Neuroscience Physiology
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!